124 related articles for article (PubMed ID: 37615198)
21. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
22. Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
Buder A; Heitzer E; Waldispühl-Geigl J; Weber S; Moser T; Hochmair MJ; Hackner K; Errhalt P; Setinek U; Filipits M
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33919291
[TBL] [Abstract][Full Text] [Related]
23. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
[TBL] [Abstract][Full Text] [Related]
24. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
[TBL] [Abstract][Full Text] [Related]
25. Circulating DNA in the neoadjuvant setting of early stage colon cancer.
Bregni G; Pretta A; Senti C; Acedo Reina E; Vandeputte C; Trevisi E; Gkolfakis P; Kehagias P; Deleporte A; Van Laethem JL; Vergauwe P; Van den Eynde M; Deboever G; Janssens J; Demolin G; Holbrechts S; Clausse M; De Grez T; Peeters M; D'Hondt L; Geboes K; Besse-Hammer T; Rothé F; Flamen P; Hendlisz A; Sclafani F
Acta Oncol; 2022 Oct; 61(10):1223-1229. PubMed ID: 35866544
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.
van Velzen MJM; Creemers A; van den Ende T; Schokker S; Krausz S; Reinten RJ; Dijk F; van Noesel CJM; Halfwerk H; Meijer SL; Mearadji B; Derks S; Bijlsma MF; van Laarhoven HWM
Gastric Cancer; 2022 Sep; 25(5):906-915. PubMed ID: 35763187
[TBL] [Abstract][Full Text] [Related]
27. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.
Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM
Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592
[TBL] [Abstract][Full Text] [Related]
28. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients.
Meng P; Wei J; Geng Y; Chen S; Terpstra MM; Huang Q; Zhang Q; Su Z; Yu W; Su M; Kok K; van den Berg A; Gu J
BMC Cancer; 2019 Aug; 19(1):818. PubMed ID: 31429737
[TBL] [Abstract][Full Text] [Related]
29. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K
Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817
[TBL] [Abstract][Full Text] [Related]
30. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
31. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
[TBL] [Abstract][Full Text] [Related]
32. Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma.
Morimoto Y; Matsuda S; Kawakubo H; Nakamura K; Kobayashi R; Hisaoka K; Okui J; Takeuchi M; Aimono E; Fukuda K; Nakamura R; Saya H; Nishihara H; Kitagawa Y
Ann Surg Oncol; 2023 Jun; 30(6):3747-3756. PubMed ID: 36788188
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
35. Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study.
Fu R; Huang J; Tian X; Liang C; Xiong Y; Zhang JT; Jiang B; Dong S; Gong Y; Gao W; Li F; Shi Y; Liu Z; Gao X; Chen R; Zhong W; Zhang Y
Mol Oncol; 2023 May; 17(5):825-838. PubMed ID: 36732646
[TBL] [Abstract][Full Text] [Related]
36. Cell-free tumour DNA analysis detects copy number alterations in gastro-oesophageal cancer patients.
Wallander K; Eisfeldt J; Lindblad M; Nilsson D; Billiau K; Foroughi H; Nordenskjöld M; Liedén A; Tham E
PLoS One; 2021; 16(2):e0245488. PubMed ID: 33539436
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.
Huffman BM; Aushev VN; Budde GL; Chao J; Dayyani F; Hanna D; Botta GP; Catenacci DVT; Maron SB; Krinshpun S; Sharma S; George GV; Malhotra M; Jurdi A; Moshkevich S; Aleshin A; Kasi PM; Klempner SJ
JCO Precis Oncol; 2022 Dec; 6():e2200420. PubMed ID: 36480779
[TBL] [Abstract][Full Text] [Related]
38. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
40. Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.
Kim MH; Kim GM; Ahn JM; Ryu WJ; Kim SG; Kim JH; Kim TY; Han HJ; Kim JY; Park HS; Park S; Park BW; Kim SI; Jeong J; Lee J; Paik S; Kim S; Jung KH; Cho EH; Sohn J
J Natl Cancer Inst; 2023 Sep; 115(9):1036-1049. PubMed ID: 37166557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]